iShares Trust - iShares Neuroscience and Healthcare ETF(IBRN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$31.67
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IBRN

11/20/2026: IBRN (1-star) is currently NOT-A-BUY. Pass it for now.

The iShares Neuroscience and Healthcare ETF (IBRN) provides targeted global equity exposure to companies advancing research, therapeutics, and medical devices focused on brain health and neurological disorders. Its main strengths lie in its pure-play thematic mandate, global reach, and robust institutional backing by BlackRock. It serves primarily as a satellite growth allocation for investors looking to capture long-term demographic healthcare trends. Key risks include high sub-sector concentration, sensitivity to clinical trial outcomes, and lighter trading liquidity given its modest asset scale. The fund suits growth-focused investors willing to accept volatility in exchange for specialized exposure to medical innovation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe fund targets innovative companies developing cutting-edge neurological therapies with significant long-term expansion potential.
Momentum investorStrong fit while signal remains positiveFavorable clinical results or sector momentum can drive sharp rallies across specialized biotech holdings.
Value investorWeak fitMany underlying constituents are pre-revenue or clinical-stage firms trading on future potential rather than current earnings.
Dividend/Income investorWeak fitThe fund emphasizes capital appreciation in innovation rather than cash distribution, offering minimal yield.
Low-risk investorWeak fitThe thematic focus on specialized healthcare and clinical-stage equities introduces elevated volatility and clinical trial risk.

Investor Profile

Ideal Investor Profile

Growth-oriented investors seeking targeted satellite exposure to specialized healthcare themes and long-term demographic trends.

Suitability

Best suited for long-term investors comfortable with thematic concentration risk and short-term volatility as part of a diversified portfolio.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighThematic biotech and medical device stocks frequently experience sharp price fluctuations based on clinical updates.
Market riskMedium / highBroader macroeconomic downturns and shifting risk appetites directly impact growth-oriented healthcare valuations.
ConcentrationHighThe fund focuses tightly on a single niche sector (neuroscience), increasing vulnerability to regulatory or sector-specific shocks.
Tracking/expenseLowThe expense ratio of 0.47% is reasonable for a specialized global thematic product.
LiquidityMedium / highLower average daily trading volumes can result in wider spreads during periods of market stress.
Business/sector qualityMediumConstituents include a mix of established medical tech leaders and speculative clinical-stage biopharmas.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

Exhibits high historical volatility consistent with specialized biotech and medical innovation funds subject to binary clinical outcomes.

Market Risk

Vulnerable to sector-specific regulatory shifts, clinical trial setbacks, and broader macroeconomic cycles affecting growth assets.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
SectorGlobal Healthcare (Neuroscience Biopharma & MedTech)98Provides comprehensive thematic exposure to companies focusing on brain health, neurological disorders, and medical device innovations.
Cash/collateralCash and Cash Equivalents2Maintains minimal liquidity reserves for operational efficiency and daily creation/redemption activities.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit 39.56%
Avg. Invested days 76
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.